Full text is available at the source.
Abstract
Cardiorenal protective glucose-lowering treatments are commonly used in managing type 2 diabetes mellitus.
- Distinct clinical phenotypes may be associated with the prescribing patterns of these treatments.
- A multilevel correlation framework was constructed to standardize the clinical application of these therapies.
- This work focuses on sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide-1 receptor agonists.
Simplified